Current Neurochemical and Pharmacological Aspects of Biogenic Amines

List of Contributors. Preface. Chapers 1. The colourful past and bright future of monoamine oxidase research. 2. Radical thoughts about the life of MAO. 3. Redox properties of flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism. 4. Stereochemistry and cofactor identity status of semicarbazide-sensitive amine oxidases. 5. Expression of human monoamine oxidase (MAO) A gene controlled by transcription factor Sp1. 6. The promotor of the human monoamine oxidase A gene. 7. Analysis of MAO-A mutations in humans. 8. The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. 9. Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls. 10. Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. 11. Some new mechanisms underlying the actions of (-)-deprenyl: possible relevance to neurogeneration. 12. Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamine: new MAO-B inhibitors without amphetamine-like properties. 13. Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. 14. Selectivity of MDL-72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma. 15. The distribution of orally administered (-)-deprenyl-propinyl-¹⁴C and (-)-deprenyl-phenyl-³H in rat brain. 16. Novel sites of action for deprenyl in MPTP-Parkinsonism: metabolite mediated protection against striatal neurotoxicity and supression of MPTP-induced increase of dopamine turnover in C57BL mice. 17. Effects of transient global ischemia and a monoamine oxidase inhibitor ifenprodil on rat brain monoamine metabolism. 18. Effects of MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain. 19. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. 20 Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R(-)-deprenyl. 21. Canine pituitary-dependent hyperadrenocorticism: A spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. 22. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: Clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy. 23. Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxidation and neurotoxicity. 24. Monoamines, cytoskeletal elements and psychiatric disorders; a neurochemical fugue. 25. Pharmacology and molecular biology of octopamine receptors from different insect species. 26. Agonist-specific coupling of G-protein-coupled receptors to second messenger systems. 27. Activation of brain 5-HT neurons by two alphamethylated tryptamine derivatives. 28. Trace amines in hepatic encephalopathy. 29. A high-affinity [³H]tryptamine binding site in human brain. 30. Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. 31. Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. 32. Semicarbazide-sensitive amine oxidases, some biochemical properties and general considerations. 33. Polyamine oxidase, properties and functions. 34. Role of aldehyde oxidase in biogenic amine metabolism. Subject index.